Anebulo Pharmaceuticals, Inc. (ANEB) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US0345691036

Price
0.28 USD
Market cap
11.42 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Anebulo Pharmaceuticals, Inc. financials

Fiscal year2025
Operating income-9.22 m USD
EBIT-8.08 m USD
Net income-8.48 m USD
Diluted EPS – continuing operations-0.25 USD

Full history since 2020, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.